Ryzodeg 70/30 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising prevalence of type 1 and type 2 diabetes, increased insulin therapy adoption, improved diagnosis of chronic diabetes, expansion of hospital-based diabetes care, availability of combination insulin formulations.

The growth in the forecast period can be attributed to increasing demand for patient-friendly insulin therapies, growing focus on long-acting insulin innovations, expansion of home-based diabetes management, rising healthcare spending on chronic diseases, increasing adoption of digital diabetes monitoring. Major trends in the forecast period include increasing adoption of fixed-ratio combination insulins, rising preference for long-acting basal-bolus therapies, growing focus on simplified diabetes treatment regimens, expansion of pen-based insulin delivery formats, enhanced emphasis on glycemic stability.

The rising prevalence of diabetes is expected to drive the growth of the Ryzodeg 70/30 market going forward. Diabetes is a chronic condition in which the body either cannot produce enough insulin or cannot use insulin effectively, resulting in elevated blood sugar levels. Factors contributing to the increasing prevalence of diabetes include unhealthy diets, sedentary lifestyles, obesity, genetic predisposition, aging populations, and improved awareness and diagnosis. Ryzodeg 70/30, a combination insulin therapy, helps manage diabetes by providing both basal and bolus insulin coverage, ensuring better blood sugar control throughout the day and night. This is critical for individuals with type 1 and type 2 diabetes to maintain stable glucose levels and achieve improved overall glycemic control. For example, in March 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it rose by 21%, with 37.9% of patients achieving target HbA1c levels. Therefore, the rising prevalence of diabetes is driving the growth of the Ryzodeg 70/30 market.

The rising healthcare expenditure is expected to support the growth of the Ryzodeg 70/30 market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on the prevention, treatment, and management of health conditions. Increasing healthcare expenditure is driven by advancements in medical technology, higher costs of innovative therapies, and greater demand for comprehensive healthcare services. This growth in spending enables broader access to advanced diabetes treatments, supports patient education programs, and facilitates investments in disease management initiatives. For instance, in December 2024, the Centers for Medicare & Medicaid Services, a US-based government agency, reported that healthcare expenditures in the United States increased by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per individual. Therefore, rising healthcare expenditure is driving the growth of the Ryzodeg 70/30 market.

The rising aging population is expected to propel the growth of the Ryzodeg 70/30 market going forward. An aging population refers to the increasing proportion of elderly individuals due to longer life expectancy and declining birth rates, which poses unique healthcare challenges. Factors contributing to the aging population include improvements in healthcare, better sanitation, socioeconomic developments, and medical advancements. Ryzodeg 70/30 supports the aging population by providing flexible, stable blood sugar control with a lower risk of hypoglycemia, improving diabetes management and overall quality of life. For example, in January 2024, the Population Reference Bureau (PRB), a US-based non-profit organization, projected that the American population aged 65 and older would increase by 47%, from 58 million in 2022 to 82 million by 2050, with this demographic rising from 17% to 23% of the total population. Therefore, the growing aging population is driving the growth of the Ryzodeg 70/30 market.

Major companies operating in the ryzodeg 70/30 market are Novo Nordisk A/S.

North America was the largest region in the ryzodeg 70/30 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ryzodeg 70/30 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ryzodeg 70/30 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the ryzodeg 70/30 market by increasing costs of imported active pharmaceutical ingredients, biologic manufacturing inputs, cold-chain logistics materials, and injectable device components. North America and Europe are most affected due to dependence on globally sourced biologics and packaging materials, while Asia-Pacific faces cost pressures in insulin formulation and export activities. These tariffs are increasing production and distribution costs for manufacturers and healthcare providers. However, they are also encouraging localized insulin manufacturing, regional supply chain diversification, and long-term investments in domestic biologics production capabilities.

The ryzodeg 70/30 market research report is one of a series of new reports that provides ryzodeg 70/30 market statistics, including ryzodeg 70/30 industry global market size, regional shares, competitors with a ryzodeg 70/30 market share, detailed ryzodeg 70/30 market segments, market trends and opportunities, and any further data you may need to thrive in the ryzodeg 70/30 industry. This ryzodeg 70/30 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ryzodeg 70/30 is a combination insulin containing 70% insulin degludec (long-acting) and 30% insulin aspart (rapid-acting). It is used to manage blood sugar levels in individuals with type 1 or type 2 diabetes, providing both immediate and sustained glucose control.

The primary indications for Ryzodeg 70/30 include type 1 diabetes and type 2 diabetes. Type 1 diabetes is an autoimmune disorder in which the body destroys insulin-producing cells in the pancreas, necessitating lifelong insulin therapy for blood sugar management. Ryzodeg 70/30 is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by end users including hospitals, clinics, home care settings, and long-term care facilities.

The ryzodeg 70/30 market consists of sales of products including the flextouch pen, novopen 5, vial, cartridge, and kwikpen. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.